Study: NCT04567303

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zifibancimig
Description: Part 1: multiple ascending doses by IVT injection. Each participant will receive zifibancimig at a constant volume of 50 microliter in the study eye.~Part 2: participants will be randomized to one of two dose levels of zifibancimig in the PD implant.~Part 3: Participants will receive one of the two dose levels of zifibancimig in the PD implant.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zifibancimig
Description: Part 1: multiple ascending doses by IVT injection. Each participant will receive zifibancimig at a constant volume of 50 microliter in the study eye.~Part 2: participants will be randomized to one of two dose levels of zifibancimig in the PD implant.~Part 3: Participants will receive one of the two dose levels of zifibancimig in the PD implant.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zifibancimig
Description: Part 1: multiple ascending doses by IVT injection. Each participant will receive zifibancimig at a constant volume of 50 microliter in the study eye.~Part 2: participants will be randomized to one of two dose levels of zifibancimig in the PD implant.~Part 3: Participants will receive one of the two dose levels of zifibancimig in the PD implant.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zifibancimig
Description: Part 1: multiple ascending doses by IVT injection. Each participant will receive zifibancimig at a constant volume of 50 microliter in the study eye.~Part 2: participants will be randomized to one of two dose levels of zifibancimig in the PD implant.~Part 3: Participants will receive one of the two dose levels of zifibancimig in the PD implant.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zifibancimig
Description: Part 1: multiple ascending doses by IVT injection. Each participant will receive zifibancimig at a constant volume of 50 microliter in the study eye.~Part 2: participants will be randomized to one of two dose levels of zifibancimig in the PD implant.~Part 3: Participants will receive one of the two dose levels of zifibancimig in the PD implant.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab
Description: Participants will receive ranibizumab 100 mg/mL through the PD implant

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Port Delivery Platform
Description: Participants will receive intraocular refillable device that is surgically inserted into the eye for continuous delivery of drugs into the vitreous.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Port Delivery Platform
Description: Participants will receive intraocular refillable device that is surgically inserted into the eye for continuous delivery of drugs into the vitreous.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Port Delivery Platform
Description: Participants will receive intraocular refillable device that is surgically inserted into the eye for continuous delivery of drugs into the vitreous.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Port Delivery Platform
Description: Participants will receive intraocular refillable device that is surgically inserted into the eye for continuous delivery of drugs into the vitreous.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Port Delivery Platform
Description: Participants will receive intraocular refillable device that is surgically inserted into the eye for continuous delivery of drugs into the vitreous.